COPENHAGEN (Reuters) – Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026. The list prices of its insulin drug Fiasp will be reduced by 75%, while the list prices of its Tresiba insulin will be reduced by […]
Health
Novo Nordisk to cut US list prices of two insulin products by more than 70%
Audio By Carbonatix
COPENHAGEN (Reuters) – Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of 2026.
The list prices of its insulin drug Fiasp will be reduced by 75%, while the list prices of its Tresiba insulin will be reduced by 72.2%, Novo said in a statement.
As a result, Novo will discontinue Tresiba’s unbranded biological versions by the end of 2025, it added.
(This story has been corrected to fix the date to ‘2025’ from ‘this year’ in paragraph 3)
(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)